Development and Production of a New Vaccine Against Cholera and Other Diseases (11070)
- *Abstract
-
Features and Benefits
- A robust and scalable cholera vaccine utilizing a new variant of recombinant cholera toxin B subunit (rCTB) created in a plant-based production system.
- High efficacy as a cholera vaccine.
- The plant-based rCTB production method is designed to produce higher yields of rCTB vaccine than other current production methods.
*This Technology is available for licensing, further development, or industrial partnering*
Technology
Cholera toxin B subunit (CTB) is a component of a known oral cholera vaccine. Traditionally, recombinant CTB (rCTB) has been produced in genetically modified bacterium. UofL Researchers created a more efficient and scalable rCTB production system using plant expression systems. UofL created a new variant of the protein by replacing its N-terminal 22-aa-propeptide with a rice-alpha-derived targeting signal which resulted in dramatic enhancement of rCTB expression (exceeding 3g/kg of leaf material within 7 days) making it a very high expression level for a plant-based expression system. UofL's new method of rCTB variant production should have the capability to produce millions of rCTB doses in a short period of time.
The UofL Researchers have also developed an extremely simple purification method for plant-expressed rCTB. The robust expression procedure together with the simple purification system for UofL's modified rCTB will significantly improve the production and utility of the vaccine antigen. Because rCTB has been widely investigated as a scaffold for various viral vaccines, autoimmune diseases and allergy, UofL's system may facilitate the development and global distribution of vaccines against cholera and other diseases.
Markets Addressed
University of Louisville researchers have identified a more efficient method of rCTB production to be used in the vaccines for cholera and other diseases. Cholera is a serious diarrheal disease caused by the pathogenic Vibrio cholerae, which leads to severe dehydration and even death within 18 hours if untreated. The current cholera vaccine contains killed V. cholerae bacteria and rCTB produced in the genetically modified bacterium. The current oral vaccine on the market has proven to be >80% effective but contains rCTB from genetically modified bacterium. Due to the limited scalability of fermentation-based production of standard rCTB, there is an unmet need for increased rCTB production methods that in turn will be used to mass produce vaccines for Cholera and other diseases. UofL's rCTB variant could be used as a scaffold for vaccines against other infectious (e.g HIV/AIDS, influenza) and non-infectious (e.g cancer, immunological disorders) diseases.
Technology Status
- IP Status: U.S. Patent Application ser.no. 14/005,388
- Development Status: Pre-clinical
- Fields of Use Available: All commercial fields
- Publications: Hamorsky et al, PL0S Negl Trop Dis., 2013, vol. 7(3):e2046.
- 国家/地区
- 美国
